blinatumomab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
mouse origin 4915 853426-35-4

Description:

MoleculeDescription

Synonyms:

  • blinatumomab
  • blincyto
  • MEDI-538
  • MT-103
a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 2018 PMDA Amgen Astellas Biopharma KK
Nov. 23, 2015 EMA Amgen Europe B.V.
Dec. 3, 2014 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute lymphocytic leukaemia recurrent 1163.24 27.78 198 5632 2071 63481121
Cytokine release syndrome 974.16 27.78 232 5598 14082 63469110
Neurotoxicity 542.94 27.78 151 5679 16839 63466353
Pyrexia 368.66 27.78 319 5511 470159 63013033
Central nervous system leukaemia 202.11 27.78 30 5800 113 63483079
Leukaemic infiltration extramedullary 169.66 27.78 24 5806 58 63483134
Blast cell count increased 116.38 27.78 22 5808 424 63482768
Acute lymphocytic leukaemia refractory 106.04 27.78 16 5814 69 63483123
Neoplasm recurrence 100.57 27.78 27 5803 2611 63480581
Graft versus host disease in skin 97.99 27.78 27 5803 2878 63480314
Intercepted product preparation error 94.99 27.78 20 5810 677 63482515
Acute lymphocytic leukaemia 87.72 27.78 24 5806 2492 63480700
Philadelphia chromosome positive 87.14 27.78 17 5813 389 63482803
Febrile neutropenia 86.93 27.78 78 5752 118371 63364821
Venoocclusive disease 78.15 27.78 21 5809 2037 63481155
Graft versus host disease 75.53 27.78 27 5803 6736 63476456
Seizure 72.03 27.78 74 5756 132560 63350632
Babesiosis 70.58 27.78 13 5817 216 63482976
Leukaemia recurrent 66.96 27.78 17 5813 1321 63481871
Therapeutic response delayed 62.19 27.78 14 5816 650 63482542
Aphasia 61.24 27.78 38 5792 32962 63450230
Tumour lysis syndrome 61.14 27.78 25 5805 8965 63474227
Venoocclusive liver disease 56.63 27.78 20 5810 4815 63478377
Graft versus host disease in gastrointestinal tract 56.17 27.78 18 5812 3223 63479969
Tremor 54.75 27.78 64 5766 132175 63351017
Nervous system disorder 54.66 27.78 29 5801 18737 63464455
CSF cell count increased 53.91 27.78 8 5822 30 63483162
Transplantation complication 49.24 27.78 9 5821 143 63483049
Escherichia bacteraemia 45.24 27.78 16 5814 3867 63479325
Neutropenia 44.95 27.78 67 5763 174938 63308254
Jaw operation 43.49 27.78 11 5819 841 63482351
Leukoencephalopathy 43.24 27.78 16 5814 4397 63478795
Drug resistance 41.50 27.78 26 5804 22907 63460285
Accidental exposure to product 39.64 27.78 27 5803 27378 63455814
Device related infection 38.55 27.78 25 5805 23367 63459825
Transformation to acute myeloid leukaemia 38.45 27.78 8 5822 255 63482937
Product preparation error 38.24 27.78 16 5814 6076 63477116
Hypoproteinaemia 38.07 27.78 12 5818 2037 63481155
Minimal residual disease 36.92 27.78 7 5823 137 63483055
Acute graft versus host disease 35.97 27.78 14 5816 4414 63478778
Hepatotoxicity 34.48 27.78 28 5802 37013 63446179
Infusion site haemorrhage 34.09 27.78 14 5816 5072 63478120
Pain 33.76 27.78 13 5817 740615 62742577
Leukaemic infiltration renal 33.44 27.78 5 5825 20 63483172
Immune effector cell-associated neurotoxicity syndrome 32.81 27.78 11 5819 2266 63480926
Neurological symptom 32.35 27.78 14 5816 5769 63477423
Acute graft versus host disease in skin 31.93 27.78 12 5818 3440 63479752
Therapy non-responder 31.81 27.78 37 5793 75864 63407328
Neutrophil count decreased 31.51 27.78 32 5798 56374 63426818
Sepsis 30.19 27.78 52 5778 153071 63330121
Interleukin level increased 29.34 27.78 7 5823 420 63482772
Death 28.40 27.78 87 5743 374294 63108898
Haemolytic transfusion reaction 28.17 27.78 4 5826 10 63483182
Disseminated intravascular coagulation 28.09 27.78 19 5811 19032 63464160

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 858.62 24.40 281 7429 22596 34926625
Acute lymphocytic leukaemia recurrent 818.00 24.40 178 7532 2866 34946355
Neurotoxicity 389.14 24.40 147 7563 17863 34931358
Pyrexia 358.49 24.40 400 7310 332613 34616608
Central nervous system leukaemia 199 24.40 37 7673 249 34948972
Blast cell count increased 191.31 24.40 45 7665 1033 34948188
Leukaemic infiltration extramedullary 185.08 24.40 30 7680 75 34949146
Acute lymphocytic leukaemia refractory 105.23 24.40 19 7691 106 34949115
Minimal residual disease 103.05 24.40 23 7687 414 34948807
Acute lymphocytic leukaemia 81.07 24.40 29 7681 3000 34946221
Aphasia 77.52 24.40 52 7658 21402 34927819
Tremor 77.20 24.40 93 7617 82494 34866727
Product preparation error 72.81 24.40 25 7685 2292 34946929
Nervous system disorder 69.34 24.40 42 7668 14501 34934720
Therapy non-responder 65.12 24.40 60 7650 39086 34910135
Cytopenia 58.74 24.40 36 7674 12687 34936534
Device related infection 55.68 24.40 39 7671 17198 34932023
Aspiration bone marrow abnormal 53.67 24.40 11 7699 129 34949092
Graft versus host disease 49.03 24.40 30 7680 10539 34938682
Encephalopathy 49.01 24.40 49 7661 35270 34913951
Febrile neutropenia 46.72 24.40 97 7613 136752 34812469
Accidental exposure to product 46.15 24.40 31 7679 12771 34936450
Blast cells present 44.32 24.40 12 7698 491 34948730
Metastases to muscle 42.27 24.40 10 7700 235 34948986
Metastases to retroperitoneum 41.83 24.40 10 7700 246 34948975
Hepatotoxicity 41.80 24.40 36 7674 21449 34927772
Graft versus host disease in gastrointestinal tract 41.73 24.40 19 7691 3664 34945557
Metastases to bone marrow 38.95 24.40 11 7699 527 34948694
Personality change due to a general medical condition 38.33 24.40 7 7703 42 34949179
Graft versus host disease in skin 37.51 24.40 18 7692 3907 34945314
Neurological symptom 36.41 24.40 18 7692 4167 34945054
Infusion site haemorrhage 36.14 24.40 12 7698 992 34948229
Metastases to spleen 35.82 24.40 10 7700 459 34948762
Confusional state 34.62 24.40 89 7621 144071 34805150
Venoocclusive disease 33.14 24.40 15 7695 2852 34946369
Chronic graft versus host disease 32.76 24.40 17 7693 4356 34944865
Off label use 32.14 24.40 179 7531 419345 34529876
Systemic mycosis 30.88 24.40 12 7698 1561 34947660
Tumour lysis syndrome 30.01 24.40 27 7683 17032 34932189
Incorrect drug administration rate 29.94 24.40 12 7698 1693 34947528
Hyperphosphataemia 29.70 24.40 16 7694 4421 34944800
Fall 28.89 24.40 5 7705 202880 34746341
Vascular device occlusion 28.18 24.40 7 7703 203 34949018
Venoocclusive liver disease 28.01 24.40 19 7691 7947 34941274
Leukoencephalopathy 27.66 24.40 15 7695 4200 34945021
Pancytopenia 27.35 24.40 63 7647 95094 34854127
Diarrhoea 26.80 24.40 28 7682 389884 34559337
CSF cell count increased 25.91 24.40 5 7705 42 34949179
Apraxia 25.39 24.40 10 7700 1348 34947873
Serum ferritin increased 24.86 24.40 16 7694 6130 34943091
Mental status changes 24.84 24.40 36 7674 38047 34911174
Acute graft versus host disease in skin 24.72 24.40 15 7695 5186 34944035
Hepatic calcification 24.69 24.40 7 7703 340 34948881

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute lymphocytic leukaemia recurrent 1553.43 23.24 307 11972 4417 79727692
Cytokine release syndrome 1410.27 23.24 420 11859 35578 79696531
Neurotoxicity 645.83 23.24 227 12052 32291 79699818
Pyrexia 538.46 23.24 586 11693 678123 79053986
Central nervous system leukaemia 315.43 23.24 55 12224 371 79731738
Leukaemic infiltration extramedullary 276.86 23.24 44 12235 151 79731958
Blast cell count increased 222.29 23.24 50 12229 1360 79730749
Acute lymphocytic leukaemia refractory 160.40 23.24 27 12252 143 79731966
Acute lymphocytic leukaemia 151.52 23.24 48 12231 4921 79727188
Febrile neutropenia 138.59 23.24 174 12105 230825 79501284
Graft versus host disease in skin 122.62 23.24 43 12236 6030 79726079
Aphasia 115.29 23.24 78 12201 46654 79685455
Tremor 113.06 23.24 135 12144 169948 79562161
Nervous system disorder 112.86 23.24 63 12216 26793 79705316
Graft versus host disease 112.26 23.24 52 12227 14974 79717135
Therapy non-responder 98.05 23.24 94 12185 92211 79639898
Graft versus host disease in gastrointestinal tract 91.22 23.24 35 12244 6321 79725788
Minimal residual disease 91.01 23.24 20 12259 487 79731622
Venoocclusive disease 90.87 23.24 32 12247 4541 79727568
Device related infection 83.99 23.24 57 12222 34237 79697872
Philadelphia chromosome positive 79.66 23.24 19 12260 671 79731438
Intercepted product preparation error 78.80 23.24 27 12252 3533 79728576
Neoplasm recurrence 78.09 23.24 28 12251 4186 79727923
Tumour lysis syndrome 73.87 23.24 46 12233 23893 79708216
Venoocclusive liver disease 73.46 23.24 36 12243 11735 79720374
Product preparation error 72.89 23.24 29 12250 5764 79726345
Cytopenia 70.14 23.24 42 12237 20341 79711768
Infusion site haemorrhage 70.00 23.24 25 12254 3695 79728414
Leukoencephalopathy 64.12 23.24 29 12250 7900 79724209
Encephalopathy 62.93 23.24 64 12215 67333 79664776
Babesiosis 57.90 23.24 13 12266 350 79731759
Seizure 57.85 23.24 104 12175 188730 79543379
CSF cell count increased 57.85 23.24 11 12268 126 79731983
Leukaemia recurrent 57.37 23.24 20 12259 2754 79729355
Acute graft versus host disease in skin 55.63 23.24 26 12253 7632 79724477
Neutropenia 54.55 23.24 130 12149 287580 79444529
Acute graft versus host disease 51.48 23.24 27 12252 10140 79721969
Blast cells present 50.20 23.24 14 12265 923 79731186
Hepatotoxicity 50.19 23.24 50 12229 51302 79680807
Escherichia bacteraemia 49.91 23.24 23 12256 6539 79725570
Pancytopenia 47.86 23.24 89 12190 165656 79566453
Therapeutic response delayed 47.47 23.24 14 12265 1128 79730981
Leukaemic infiltration renal 45.01 23.24 7 12272 20 79732089
Chronic graft versus host disease 43.09 23.24 21 12258 6760 79725349
Off label use 42.45 23.24 261 12018 906954 78825155
Metastases to muscle 42.01 23.24 10 12269 350 79731759
Disseminated intravascular coagulation 40.88 23.24 38 12241 35804 79696305
Metastases to retroperitoneum 40.87 23.24 10 12269 394 79731715
Transformation to acute myeloid leukaemia 40.47 23.24 12 12267 985 79731124
Neutrophil count decreased 39.90 23.24 60 12219 93899 79638210
Apraxia 38.34 23.24 15 12264 2852 79729257
Metastases to bone marrow 38.25 23.24 11 12268 811 79731298
Jaw operation 38.15 23.24 11 12268 818 79731291
Fall 37.72 23.24 14 12265 487615 79244494
Accidental exposure to product 37.26 23.24 34 12245 31288 79700821
Dyspnoea 36.74 23.24 47 12232 856978 78875131
Metastases to spleen 36.24 23.24 10 12269 634 79731475
Drug hypersensitivity 34.91 23.24 3 12276 298913 79433196
Bone marrow failure 34.59 23.24 41 12238 51066 79681043
Pain 34.03 23.24 35 12244 703767 79028342
Dysgraphia 33.40 23.24 15 12264 4017 79728092
Fusarium infection 33.29 23.24 12 12267 1820 79730289
Blood lactate dehydrogenase increased 32.61 23.24 35 12244 39135 79692974
Neurological symptom 32.57 23.24 19 12260 8764 79723345
Systemic mycosis 32.34 23.24 13 12266 2653 79729456
Diarrhoea 32.14 23.24 54 12225 880435 78851674
Aspiration bone marrow abnormal 32.03 23.24 7 12272 166 79731943
Platelet count decreased 31.63 23.24 83 12196 194581 79537528
Pruritus 31.07 23.24 11 12268 394637 79337472
Joint swelling 30.88 23.24 4 12275 288642 79443467
Blood bilirubin increased 30.57 23.24 44 12235 66188 79665921
Serum ferritin increased 30.57 23.24 19 12260 9828 79722281
Precursor B-lymphoblastic lymphoma recurrent 30.47 23.24 5 12274 22 79732087
Cytomegalovirus infection 30.17 23.24 35 12244 42609 79689500
Personality change due to a general medical condition 29.69 23.24 7 12272 235 79731874
Disease progression 29.33 23.24 78 12201 184284 79547825
Condition aggravated 28.96 23.24 21 12258 501103 79231006
Fatigue 27.89 23.24 64 12215 929663 78802446
Thrombocytopenia 27.87 23.24 97 12182 265162 79466947
Interleukin level increased 27.81 23.24 8 12271 590 79731519
Trichosporon infection 27.70 23.24 9 12270 999 79731110
Capillary leak syndrome 27.50 23.24 13 12266 3912 79728197
Transplantation complication 27.37 23.24 7 12272 331 79731778
Hyperphosphataemia 26.89 23.24 15 12264 6361 79725748
Hepatic calcification 26.70 23.24 7 12272 365 79731744
White blood cell count increased 26.61 23.24 44 12235 74589 79657520
Confusional state 26.54 23.24 108 12171 317889 79414220
Neoplasm progression 26.33 23.24 36 12243 51646 79680463
Transaminases increased 26.29 23.24 36 12243 51707 79680402
Alanine aminotransferase increased 26.07 23.24 69 12210 162501 79569608
Adrenomegaly 26.01 23.24 7 12272 404 79731705
Lymphocyte count decreased 25.71 23.24 34 12245 47255 79684854
Ataxia 25.61 23.24 25 12254 25014 79707095
Lineage switch leukaemia 25.57 23.24 4 12275 12 79732097
Nausea 25.51 23.24 70 12209 957126 78774983
Haemolytic transfusion reaction 25.33 23.24 4 12275 13 79732096
Procalcitonin increased 24.32 23.24 11 12268 2995 79729114
Hypoproteinaemia 24.13 23.24 12 12267 4034 79728075
Drug resistance 23.95 23.24 31 12248 42182 79689927
Costal cartilage fracture 23.90 23.24 6 12273 263 79731846
Chronic graft versus host disease in skin 23.78 23.24 9 12270 1565 79730544
Hypogammaglobulinaemia 23.61 23.24 18 12261 12933 79719176

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA CS M0018640 Recombinant Fusion Proteins
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000175617 CD3-directed Antibody Interactions
FDA MoA N0000175618 CD3 Receptor Agonists
FDA EPC N0000191421 Bispecific CD19-directed CD3-directed T Cell Engager
FDA MoA N0000191422 CD19-directed Antibody Interactions

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pre B-cell acute lymphoblastic leukemia indication 277572006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
B-lymphocyte antigen CD19 Surface antigen ANTIBODY BINDING Kd 9 IUPHAR DRUG LABEL
T-cell surface glycoprotein CD3 Surface antigen ANTIBODY BINDING Kd 7 IUPHAR DRUG LABEL

External reference:

IDSource
4FR53SIF3A UNII
D09325 KEGG_DRUG
4033958 VUID
N0000191284 NUI
4033958 VANDF
C3853839 UMLSCUI
CHEMBL1742992 ChEMBL_ID
DB09052 DRUGBANK_ID
9028 INN_ID
C510808 MESH_SUPPLEMENTAL_RECORD_UI
7384 IUPHAR_LIGAND_ID
C568788 MESH_SUPPLEMENTAL_RECORD_UI
1597258 RXNORM
231126 MMSL
30709 MMSL
d08312 MMSL
015799 NDDF
716122004 SNOMEDCT_US
774173007 SNOMEDCT_US

Pharmaceutical products:

None